{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:44:52Z","timestamp":1786981492448,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["No DEC-2017\/25\/N\/NZ3\/01039"],"award-info":[{"award-number":["No DEC-2017\/25\/N\/NZ3\/01039"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Overexpression of ATP-binding cassette (ABC) transporters causing multidrug resistance (MDR) in cancer cells is one of the major obstacles in cancer chemotherapy. The 5-FU resistant subclone (HL-60\/5FU) of the human HL-60 promyelocytic leukemia cell line was selected by the conventional method of continuous exposure of the cells to the drug up to 0.08\u00a0mmol\/L concentration. HL-60\/5FU cells exhibited six-fold enhanced resistance to 5-FU than HL-60 cells. RT-PCR and ELISA assay showed significant overexpression of MDR-related ABC transporters, ABCB1, ABCG2 but especially ABCC1 in the HL-60\/5FU as compared with the parental cell line. Three novel synthetic 5-methylidenedihydrouracil analogs, U-236, U-332 and U-359, selected as highly cytotoxic for HL-60 cells in MTT test, showed similar cytotoxicity in the resistant cell line. When co-incubated with 5-FU, these analogs were found to down-regulate the expression of all three transporters. However, the most pronounced effect was caused by U-332 which almost completely abolished ABCC1 expression in the resistant HL-60\/5FU cells. Additionally, U-332 inhibited the activity of ATPase, an enzyme which catalyzes hydrolysis of ATP, providing energy to efflux drugs from the cells through the cellular membranes. Taken together, the obtained data suggest that acquired 5-FU resistance in HL-60\/5FU cells results from overexpression of ABCC1 and that targeting ABCC1 expression could be a potential approach to re-sensitize resistant leukemia cells to 5-FU. The synthetic uracil analog U-332, which can potently down-regulate ABC transporter expression and therefore disturb drug efflux, can be considered an efficient ABCC1 regulator in cancer cells.<\/jats:p>","DOI":"10.1007\/s11033-019-05017-w","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T09:02:38Z","timestamp":1574067758000},"page":"5831-5839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["New uracil analogs as downregulators of ABC transporters in 5-fluorouracil-resistant human leukemia HL-60 cell line"],"prefix":"10.1007","volume":"46","author":[{"given":"Angelika","family":"D\u0142ugosz-Pokorska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlena","family":"Pi\u0119ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Janecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5178-4464","authenticated-orcid":false,"given":"Anna","family":"Janecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,18]]},"reference":[{"key":"5017_CR1","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1242\/dmm.015974","volume":"7","author":"CS Grove","year":"2014","unstructured":"Grove CS, Vassiliou GS (2014) Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? Dis Model Mech 7:941\u2013951","journal-title":"Dis Model Mech"},{"key":"5017_CR2","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.2147\/OTT.S191621","volume":"12","author":"J Zhang","year":"2019","unstructured":"Zhang J, Gu Y, Chen B (2019) Mechanisms of drug resistance in acute myeloid leukemia. OncoTargets Ther 12:1937","journal-title":"OncoTargets Ther"},{"key":"5017_CR3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1046\/j.1365-2141.2001.03171.x","volume":"115","author":"P Sonneveld","year":"2001","unstructured":"Sonneveld P, Suciu S, Weijermans P, Beksa\u00e7 M, Neuwirtova R, Solbu G, Segeren CM (2001) Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC\u2013HOVON randomized phase III study (06914). Brit J Haematol 115:895\u2013902","journal-title":"Brit J Haematol"},{"key":"5017_CR4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1028-4559(09)60296-5","volume":"48","author":"FS Liu","year":"2009","unstructured":"Liu FS (2009) Mechanisms of chemotherapeutic drug resistance in cancer therapy-a quick review. Taiwan J Obstet Gynecol 48:239\u2013244","journal-title":"Taiwan J Obstet Gynecol"},{"key":"5017_CR5","first-page":"339","volume":"7","author":"B Mansoori","year":"2017","unstructured":"Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B (2017) The different mechanisms of cancer drug resistance: a brief review. APB 7:339","journal-title":"APB"},{"key":"5017_CR6","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.2174\/1381612822666160302103646","volume":"22","author":"A D\u0142ugosz","year":"2016","unstructured":"D\u0142ugosz A, Janecka A (2016) ABC transporters in the development of multidrug resistance in cancer therapy. Curr Pharm Design 22:4705\u20134716","journal-title":"Curr Pharm Design"},{"key":"5017_CR7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1023\/A:1012866803188","volume":"33","author":"MM Gottesman","year":"2001","unstructured":"Gottesman MM, Ambudkar SV (2001) Overview: ABC transporters and human disease. J Bioenerg Biomembr 33:453\u2013458","journal-title":"J Bioenerg Biomembr"},{"key":"5017_CR8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.genom.6.080604.162122","volume":"6","author":"M Dean","year":"2005","unstructured":"Dean M, Annilo T (2005) Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genom Hum Genet 6:123\u2013142","journal-title":"Annu Rev Genom Hum Genet"},{"key":"5017_CR9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/cyto.b.20403","volume":"74","author":"LL de Figueiredo-Pontes","year":"2008","unstructured":"de Figueiredo-Pontes LL, Pint\u00e3o MCT, Oliveira LC, Dalmazzo LF, J\u00e1como RH, Garcia AB, Rego EM (2008) Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytom B 74:163\u2013168","journal-title":"Cytom B"},{"key":"5017_CR10","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1007\/s12032-011-0117-4","volume":"29","author":"J Chen","year":"2009","unstructured":"Chen J, Tian W, Cai H, He H, Deng Y (2009) Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol 29:2527\u20132534","journal-title":"Med Oncol"},{"key":"5017_CR11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5732\/cjc.011.10320","volume":"31","author":"T Nakanishi","year":"2012","unstructured":"Nakanishi T, Ross DD (2012) Breast cancer resistance protein (BCRP\/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer Res 31:73\u201399","journal-title":"Chin J Cancer Res"},{"key":"5017_CR12","first-page":"2532","volume":"59","author":"JH Hooijberg","year":"1999","unstructured":"Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansenl G (1999) Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59:2532\u20132535","journal-title":"Cancer Res"},{"key":"5017_CR13","first-page":"3205","volume":"6","author":"DM van der Kolk","year":"2000","unstructured":"van der Kolk DM, de Vries EG, van Putten WL, Verdonck LF, Ossenkoppele GJ, Verhoef GE, Vellenga E (2000) P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 6:3205\u20133214","journal-title":"Clin Cancer Res"},{"key":"5017_CR14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10911-009-9109-9","volume":"14","author":"M Dean","year":"2009","unstructured":"Dean M (2009) ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 14:3\u20139","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"5017_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbi.2015.07.011","volume":"242","author":"A Paszel-Jaworska","year":"2015","unstructured":"Paszel-Jaworska A, Rubi\u015b B, Bednarczyk-Cwynar B, Zaprutko L, Rybczy\u0144ska M (2015) Proapoptotic activity and ABCC1-related multidrug resistance reduction ability of semisynthetic oleanolic acid derivatives DIOXOL and HIMOXOL in human acute promyelocytic leukemia cells. Chem Biol Interact 242:1\u201312","journal-title":"Chem Biol Interact"},{"key":"5017_CR16","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.3892\/ol.2017.5741","volume":"13","author":"D Cao","year":"2017","unstructured":"Cao D, Qin S, Mu Y, Zhong M (2017) The role of MRP1 in the multidrug resistance of colorectal cancer. Oncol Lett 13:2471\u20132476","journal-title":"Oncol Lett"},{"key":"5017_CR17","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.oraloncology.2011.08.005","volume":"47","author":"BL Cai","year":"2011","unstructured":"Cai BL, Xu XF, Fu SM, Shen LL, Zhang J, Guan M, Wu JZ (2011) Nuclear translocation of MRP1 contributes to multidrug resistance of mucoepidermoid carcinoma. Oral Oncol 47:1134\u20131140","journal-title":"Oral Oncol"},{"key":"5017_CR18","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/annonc\/mdh264","volume":"15","author":"P Noordhuis","year":"2004","unstructured":"Noordhuis P, Holwerda U, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Peters GJ (2004) 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol 15:1025\u20131032","journal-title":"Ann Oncol"},{"key":"5017_CR19","doi-asserted-by":"crossref","first-page":"e64961","DOI":"10.1371\/journal.pone.0064961","volume":"8","author":"A de la Cueva","year":"2013","unstructured":"de la Cueva A, de Molina AR, \u00c1lvarez-Ayerza N, Ramos MA, Cebri\u00e1n A, del Pulgar TG, Lacal JC (2013) Combined 5-FU and ChoK\u03b1 inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts. PLoS ONE 8:e64961\u2013e64974","journal-title":"PLoS ONE"},{"key":"5017_CR20","doi-asserted-by":"crossref","first-page":"e0115686","DOI":"10.1371\/journal.pone.0115686","volume":"10","author":"C Focaccetti","year":"2015","unstructured":"Focaccetti C, Bruno A, Magnani E, Bartolini D, Principi E, Dallaglio K, Albini A (2015) Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS ONE 10:e0115686\u2013e0115698","journal-title":"PLoS ONE"},{"key":"5017_CR21","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.3748\/wjg.v22.i10.2971","volume":"22","author":"K Gao","year":"2016","unstructured":"Gao K, Liang Q, Zhao ZH, Li YF, Wang SF (2016) Synergistic anticancer properties of docosahexaenoic acid and 5-fluorouracil through interference with energy metabolism and cell cycle arrest in human gastric cancer cell line AGS cells. World J Gastroenterol 22:2971\u20132980","journal-title":"World J Gastroenterol"},{"key":"5017_CR22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1042\/bse0500209","volume":"50","author":"A Tamaki","year":"2011","unstructured":"Tamaki A, Ierano C, Szakacs G, Robey RW, Bates SE (2011) The controversial role of ABC transporters in clinical oncology. Essays Biochem 50:209\u2013232","journal-title":"Essays Biochem"},{"key":"5017_CR23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10593-012-0960-z","volume":"48","author":"A Gomtsyan","year":"2012","unstructured":"Gomtsyan A (2012) Heterocycles in drugs and drug discovery. Chem Heterocycl Compd 48:7\u201310","journal-title":"Chem Heterocycl Compd"},{"key":"5017_CR24","doi-asserted-by":"crossref","first-page":"10257","DOI":"10.1021\/jm501100b","volume":"57","author":"E Vitaku","year":"2014","unstructured":"Vitaku E, Smith DT, Njardarson JT (2014) Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among US FDA approved pharmaceuticals: miniperspective. J Med Chem 57:10257\u201310274","journal-title":"J Med Chem"},{"key":"5017_CR25","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.bmc.2018.03.032","volume":"26","author":"D Mondal","year":"2018","unstructured":"Mondal D, Koehn EM, Yao J, Wiemer DF, Kohen A (2018) Chemo-enzymatic synthesis of the exocyclic olefin isomer of thymidine monophosphate. Bioorg Med Chem 26:2365\u20132371","journal-title":"Bioorg Med Chem"},{"key":"5017_CR26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2407-9-56","volume":"9","author":"ZX Du","year":"2009","unstructured":"Du ZX, Zhang HY, Meng X, Guan Y, Wang HQ (2009) Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells. BMC Cancer 9:56","journal-title":"BMC Cancer"},{"key":"5017_CR27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5604\/17322693.1199712","volume":"70","author":"E Drozd","year":"2016","unstructured":"Drozd E, Gruber B, Marczewska J, Drozd J, Anuszewska E (2016) Intracellular glutathione level and efflux in human melanoma and cervical cancer cells differing in doxorubicin resistance. Postepy Hig Med Dosw 70:319\u2013328","journal-title":"Postepy Hig Med Dosw"},{"key":"5017_CR28","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.tet.2019.03.024","volume":"75","author":"M Pi\u0119ta","year":"2019","unstructured":"Pi\u0119ta M, K\u0119dzia J, Kowalczyk D, Wojciechowski J, Wolf WM, Janecki T (2019) Enantioselective synthesis of 5-methylidenedihydrouracils as potential anticancer agents. Tetrahedron 75:2495\u20132505","journal-title":"Tetrahedron"},{"key":"5017_CR29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55\u201363","journal-title":"J Immunol Methods"},{"key":"5017_CR30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/abio.1999.4085","volume":"15","author":"J Winer","year":"1999","unstructured":"Winer J, Jung CK, Shackel I, Williams P (1999) Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 15:41\u201349","journal-title":"Anal Biochem"},{"key":"5017_CR31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.bbamem.2009.11.022","volume":"1798","author":"P Nervi","year":"2010","unstructured":"Nervi P, Li-Blatter X, \u00c4\u00e4nismaa P, Seelig A (2010) P-glycoprotein substrate transport assessed by comparing cellular and vesicular ATPase activity. BBA-Biomembranes 1798:515\u2013525","journal-title":"BBA-Biomembranes"},{"key":"5017_CR32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1042\/BJ20060632","volume":"401","author":"Y Kimura","year":"2007","unstructured":"Kimura Y, Kioka N, Kato H, Matsuo M, Ueda K (2007) Modulation of drug-stimulated ATPase activity of human MDR1\/P-glycoprotein by cholesterol. Biochem J 401:597\u2013605","journal-title":"Biochem J"},{"key":"5017_CR33","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.014605","author":"H Glavinas","year":"2007","unstructured":"Glavinas H, Kis E, Pal A, Kovacs R, Jani M, Vagi E, Bathori G (2007) ABCG2 (BCRP\/MXR) ATPase assay-a useful tool to detect drug-transporter interactions. Drug Met Disp. https:\/\/doi.org\/10.1124\/dmd.106.014605","journal-title":"Drug Met Disp"},{"key":"5017_CR34","doi-asserted-by":"crossref","first-page":"44541","DOI":"10.1038\/srep44541","volume":"7","author":"V Lopes-Rodrigues","year":"2017","unstructured":"Lopes-Rodrigues V, Di Luca A, Mleczko J, Meleady P, Henry M, Pesi M, Falcon-Perez JM (2017) Identification of the metabolic alterations associated with the multidrug resistant phenotype in cancer and their intercellular transfer mediated by extracellular vesicles. Sci Rep-UK 7:44541\u201344580","journal-title":"Sci Rep-UK"},{"key":"5017_CR35","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2174\/138920011795101804","volume":"12","author":"M Honorat","year":"2011","unstructured":"Honorat M, Falson P, Terreux R, Di Pietro A, Dumontet C, Payen L (2011) Multidrug resistance ABC transporter structure predictions by homology modeling approaches. Curr Drug Metab 12:268\u2013277","journal-title":"Curr Drug Metab"},{"key":"5017_CR36","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/jcpt.12197","volume":"39","author":"A Au","year":"2014","unstructured":"Au A, Baba AA, Azlan H, Norsa\u2019adah B, Ankathil R (2014) Clinical impact of ABCC1 and ABCC2 genotypes and haplotypes in mediatingimatinib resistance among chronic myeloid leukaemia patients. J Clin Pharm Ther 39:685\u2013690","journal-title":"J Clin Pharm Ther"},{"key":"5017_CR37","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jmb.2017.01.010","volume":"429","author":"O Lewinson","year":"2017","unstructured":"Lewinson O, Livnat-Levanon N (2017) Mechanism of action of ABC importers: conservation, divergence, and physiological adaptations. J Mol Biol 429:606\u2013619","journal-title":"J Mol Biol"},{"key":"5017_CR38","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.phrs.2017.04.025","volume":"121","author":"A Patel","year":"2017","unstructured":"Patel A, Li TW, Anreddy N, Wang DS, Sodani K, Gadhia S, Chen ZS (2017) Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport. Pharmacol Res 121:184\u2013193","journal-title":"Pharmacol Res"},{"key":"5017_CR39","doi-asserted-by":"crossref","first-page":"30880","DOI":"10.1074\/jbc.R114.609248","volume":"289","author":"SP Cole","year":"2014","unstructured":"Cole SP (2014) Multidrug resistance protein 1 (MRP1, ABCC1), a \u201cmultitasking\u201d ATP-binding cassette (ABC) transporter. J Biol Chem 289:30880\u201330888","journal-title":"J Biol Chem"},{"key":"5017_CR40","first-page":"273","volume":"5","author":"L Li","year":"2014","unstructured":"Li L, Xiao-Dong L (2014) Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances. Front Pharmacol 5:273\u2013282","journal-title":"Front Pharmacol"},{"key":"5017_CR41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fonc.2014.00041","volume":"4","author":"FJ Sharom","year":"2014","unstructured":"Sharom FJ (2014) Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: its role in modulating protein function. Front Oncol 4:41\u201360","journal-title":"Front Oncol"},{"key":"5017_CR42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.tips.2010.11.007","volume":"32","author":"DD Mruk","year":"2011","unstructured":"Mruk DD, Su L, Cheng CY (2011) Emerging role for drug transporters AT the blood-testis barier. Trends Pharmacol Sci 32:99\u2013106","journal-title":"Trends Pharmacol Sci"},{"key":"5017_CR43","first-page":"27","volume":"7","author":"ML Amin","year":"2013","unstructured":"Amin ML (2013) P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7:27\u201334","journal-title":"Drug Target Insights"},{"key":"5017_CR44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/107327480301000207","volume":"10","author":"H Thomas","year":"2003","unstructured":"Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10:159\u2013165","journal-title":"Cancer Control"},{"key":"5017_CR45","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.biotechadv.2013.06.004","volume":"31","author":"M Saraswathy","year":"2013","unstructured":"Saraswathy M, Gong S (2013) Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv 31:1397\u20131407","journal-title":"Biotechnol Adv"},{"key":"5017_CR46","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1016\/j.febslet.2006.02.020","volume":"580","author":"T Ozben","year":"2006","unstructured":"Ozben T (2006) Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 580:2903\u20132909","journal-title":"FEBS Lett"},{"key":"5017_CR47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drup.2017.10.003","volume":"32","author":"I Genovese","year":"2017","unstructured":"Genovese I, Ilari A, Assaraf YG, Fazi F, Colotti G (2017) Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resist Update 32:23\u201346","journal-title":"Drug Resist Update"},{"key":"5017_CR48","first-page":"3481","volume":"9","author":"GJ Gozzi","year":"2015","unstructured":"Gozzi GJ, Bouaziz Z, Winter E, Daflon-Yunes N, Honorat M, Guragossian N, Pinaud N (2015) Phenolic indeno [1, 2-b] indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity. Drug Des Dev Ther 9:3481\u20133493","journal-title":"Drug Des Dev Ther"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-019-05017-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11033-019-05017-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-019-05017-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T19:20:38Z","timestamp":1605554438000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11033-019-05017-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,18]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5017"],"URL":"https:\/\/doi.org\/10.1007\/s11033-019-05017-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,18]]},"assertion":[{"value":"5 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author(s) declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}